2018, Number 2
<< Back Next >>
Rev Latin Infect Pediatr 2018; 31 (2)
Consensus of the Mexican Association of Pediatric Infectious Diseases (AMIP) on the impact of vaccination in reducing the burden of pneumococcal disease in Mexico, 2018
Ortiz-Ibarra FJ, Luévanos-Velázquez A, González SN, Reyna-Figueroa J, Chacón CE, Echaniz AG, Ecil SJ, García VL, Gómez ACM, Hernández PM, Matías JNA, Nakamura LMÁ, Otero MFJ, Saltigeral SP, Solórzano SF, Treviño VPD, Vázquez NJA, Xóchihua DL, Ávila-Agüero ML
Language: Spanish
References: 54
Page: 62-75
PDF size: 341.16 Kb.
ABSTRACT
Infections caused by
Streptococcus pneumoniae are considered among the main causes of morbidity and mortality in children under two years of age, adults over 65 years of age and immunocompromised hosts. The objective of this consensus, is to analyze and discuss the vaccination impact on the burden of pneumococcal diseases in Mexico and Latin America.
Methods: Through an academic consensus model, the available scientific literature of the topics considered controversial were analyzed and discussed. The recommendation of the “Guidelines for the elaboration of consensus” guide; as well as the recommendations and useful criteria for the critical reading of the selected articles of the AGREE (Appraisal of Guidelines for Research & Evaluation) European initiative were followed. Mixed and representative teams with the Pediatricians, Infectious Diseases specialists and microbiologists participation were integrated. A selective search of the studies and manuscripts used for this review was performed. The identification of the articles was carried out using the keywords:
Streptococcus pneumoniae, conjugate pneumococcal vaccine, epidemiology, interchangeability, immunity and antimicrobial resistance; and those that covered the period of January 2013 to May 2018 were chosen. Articles published in English and Spanish on PubMed, Google Scholar, EMBASE and Cochrane search engines were selected.
Results: A total of nine relevant and controversial issues were raised, to which an analysis was made, and recommendations were established under the results of the critical review of the selected articles.
REFERENCES
González-Romo F, Picazo JJ, García Rojas A, Labrador Horrillo M, Barrios V, Magro MC et al. Consenso sobre la vacunación antineumocócica en el adulto por riesgo de edad y patología de base. Actualización 2017. Rev Esp Quimioter. 2017; 30 (2): 142-168.
Instituto de Salud Pública. Ministerio de Salud de Chile. Comportamiento de Streptococcus pneumoniae serotipos 3 y 19A en Chile, años 2007-2015. 2016 [Consultado 18 mayo 2018]; 6 (2): Disponible en: http://www.ispch.cl/sites/default/files/Boletin%20S.pneumoniae%2019A%20y%203.pdf
Soto-Noguerón A, Carnalla-Barajas NM, Cornejo-Juárez P, Volkow-Fernández P, Velázquez-Meza ME, Echániz-Aviles G. Streptococcus pneumoniae: distribution of serotypes and antimicrobial susceptibility in patients with cancer. Salud Pública Mex. 2018; 60 (1): 21-28.
WHO. Pneumococcal conjugate vaccine for childhood immunization.WHO position paper. Weekly Epidemiol Rec. 2012; 87(12): 129-144.
Ferrario C, Califano G, Durán P, Maccarone M, Miceli I, Manterola A et al. Lineamientos para la elaboración de consensos. Arch Argent Pediatr. 2012; 110 (2): 163-167. doi: org/10.5546/aap.2012.163.
The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Disponible en: https://www.agreetrust.org/resource-centre/the-original-agree-instrument/
Birtwhistle R, Pottie K, Shaw E, Dickinson JA, Brauer P, Fortin M et al. Canadian task force on preventive health care: ¡we’re back! Can Fam Physician. 2012; 58 (1): 13-15.
Manterola C, Asenjo-Lobos C, Otzen T. Jerarquización de la evidencia. Niveles de evidencia y grados de recomendación de uso actual. Rev Chilena Infectol. 2014; 31 (6): 705-718.
Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 7.a ed. Editorial Elsevier; 2012. pp. 2627-2630.
Fonseca F, Martínez A, Montes de Oca M, Cardoso E, Reyes A. Enfermedad neumocócica invasiva en niños menores de 6 años hospitalizados. Revista Cubana de Pediatr. 2017; 89.
DGEPI. Anuario de morbilidad 1984-2017. [Consultado el 18 mayo 2018] Disponible en: http://www.epidemiologia.salud.gob.mx/anuario/html/anuarios.html
Tamayo C, Pajaro M, Díaz D. Enfermedad neumocócica e infecciones relacionadas en pacientes pediátricos egresados del hospital infantil sur de Santiago de Cuba. Rev Cubana Pediatr. 2017; 89; 119-132.
Sabin Vaccine Institute. Carga de la enfermedad neumocócica en América latina y el caribe. Análisis de la evidencia. [Consultado el 18 mayo 2018] Disponible en: https://www.sabin.org/sites/sabin.org/files/delahoz.1.pdf
GIVEPac. Grupo Interinstitucional para la vigilancia de enfermedades bacterianas prevenibles por vacunación 2016. Datos por sexo y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Staphylococcus aureus en procesos infecciosos. [Consultado el 19 mayo 2018] Disponible en: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
Jiménez P, Serviá M. Análisis descriptivo de las meningitis por Streptococcus pneumoniae en un hospital terciario. Neurol Arg. 2012; 4 (1): 6-10.
Castañeda E, Agudelo CI, De Antonio R, Rosselli D, Calderón C, Ortega-Barria E, Colindres R. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010. Infectious Diseases. [Internet]. 2012 [Consultado el 24 sep 2015]; 12 (124). Disponible en: http://www.biomedcentral.com/content/pdf/1471-2334-12-124.pdf
Isturiz R, Sings H, Hilton B, Arguedas A, Reinert R, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Review Vaccines. 2017; 16 (10): 1007-1027. doi: 10.1080/14760584.2017.1362339
Ortiz-Prado E, Iturralde AL, Hernández P, Galarza C. Las vacunas conjugadas y la enfermedad neumocócica en Ecuador. Vacunas. 2014; 15 (3-4): 73-79.
Echániz G, San Román L, Sánchez M, Carnalla MN, Soto A. Prevalencia de Streptococcus pneumoniae serotipo 19A antes y después de la introducción de la vacuna conjugada heptavalente en México. Salud Pública Mex. 2014; 56 (3): 266-271.
ALAPE. Opinión del consejo directivo ALAPE sobre vacunación antineumocócica 2017. [Consultado el 24 mayo 2018]. Disponible en: http://www.alape.org/docs/documentos/Comunicado_vacunaneumococo.pdf.
Potin M, Fica A, Wilhem J, Cerda J, Contreras L, Escobar C et al. Opinión del Comité Consultivo de Inmunizaciones Sociedad Chilena de Infectología. Vacuna neumocócica conjugada en niños y la emergencia de serotipo 19A. Rev Chil Infectol. 2016; 33 (3): 304-306.
Brandileone MC, Almeida SC, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018; 36 (19): 2559-2566.
Olarte L, Kaplan S, Barson WJ, Romero JR, Ling Lin P, Tan TQ et al. Emergence of multidrug-resistant pneumococcal serotype 35B among Children in the United States. J Clin Mocrobiol. 2017; 55 (3): 724-734.
Schillberg E, Isaac M, Deng X, Peirano G, Wylie L, Caeseele PV et al. Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009-2011. Clin Infect Dis. 2014; 59 (5): 651-657.
Echaniz-Avilés G, Soto-Noguerón A, Miranda-Novales G, Carnalla-Barajas MN, Velázquez-Meza ME, Solórzano-Santos F et al. Streptococcus pneumoniae serotypes identified in Mexican children with invasive disease before and after the introduction of PCV7 (1993-2012). Arch Med Res. 2015; 46 (2): 149-153.
Chacón-Cruz E, Velazco-Mendez Y, Navarro-Álvarez S, Rivas-Landeros RM, Volker ML, Lopez-Espinoza G. Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital. J Infect Dev Ctries. 2012; 6 (6): 516-520.
Chacón E, Rivas RM, Volker ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines. 2014; 2 (6): 155-158.
Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13. J Antimicrob Chemother. 2015; 70 (8): 2199-2202.
Karnezis TT, Smith A, Whittier S, Haddad J, Saiman L. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS One. 2009; 4 (6): e5965.
Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016; 62 (9): 1119-1125.
Limón RA, Reyna FJ, Rivera CM, Kusunoki GW, Espinosa ML, Montiel OA. Prevalence of Streptotococcus pneumoniae in nasopharyngeal isolates from children attending in care-day centers of Petróleos Mexicanos. Enf Infec Microbiol. 2008; 28: 99-105.
Solórzano-Santos F, Ortiz-Ocampo, Miranda-Novales MG, Echániz-Avilés G, Soto-Noguerón A, Guiscafré-Gallardo H. Serotipos prevalentes de Streptococcus pneumoniae colonizadores de nasofaringe en niños del Distrito Federal. Salud Pública Mex. 2005; 47 (4): 276-281.
Miranda NM, Solórzano SF, Guiscafré GH, Leaños MB, Echániz AG et al. Streptococcus pneumoniae: low frecuency of penicillin resistance and high resistance to trimethoprim sulfamethoxazol in nasopharyngeal isolates in children in a rural area in México. Arch Med Research. 1997; 28 (4): 559-563.
Espinosa de los Monteros LE, Aguilar-Ituarte F, Jiménez-Juárez R, Rodríguez- Suárez, Gómez-Barreto D. Reemplazo de serotipos de Streptococcus pneumoniae en niños con vacuna conjugada antineumocóccica 7V en México. Salud Pública Méx. 2010; 52 (1): 14-13.
Brandileone MC, Zanella RC, Almeida SC, Brandao AP, Ribeiro AF, Carvalhanas TM et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo, Brazil. Vaccine. 2016; 34 (46): 5604-5611. doi: 10.1016/j.vaccine.2016.09.027
Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. J Infect Dis. 2015; 211 (7): 1144-1153.
Gentile A, Bakir J, Bialorus L, Caruso L, Mirra D, Santander C et al. Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of consolidated pneumonia in children younger than 5 years old in Pilar, Buenos Aires: A population-based study. Arch Argent Pediatr. 2015; 113 (6): 502-509.
Glikman D, Dagan R, Barkai G, Averbuch D, Guri A, Givon-Lavi N et al. Dynamic of severe an non-sereve invasive pneumococcal disease in young children in Israel following PCV 7/PCV 13 introduction. Pediatr Infect Dis J. 2018; doi: 101097/INF.0000000000002100.
Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007; 196 (9): 1346-1354.
Wijmenga-Monsuur AJ, Van Westen E, Knol MJ, Jongerius RMC, Zancolli M, Goldblatt D et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS One. 2015M 11 (5): e0155088. https://doi.org/10.1371/journal.pone.0155088
Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in finnish children—A population-based study. PLoS One. 2015; 10 (3): e0120290. doi: 10.1371/journal.pone.0120290
Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018; 36 (15): 1934-1940. doi: org/10.1016/j.vaccine.2018.03.001
Naucler P, Galanis I, Morfeldt E , Darenberg J, Örtqvist A, Henriques-Normark B et al. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017; 65 (11): 1780-1789.
Ávila-Aguero ML, Ulloa-Gutierrez R, Falleiros-Arlant LH, Porras O. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A? Expert Rev Vaccines. 2017; 16 (7): 10.1080/14760584.2017.1334555
Ciapponi A, Lee A, Bardach MA, Glujovsky D, Ares LR, Cafferata ML et al. Interchangeability between pneumococcal conjugate vaccines: a systematic review and meta-analysis. Value Health Reg Issues. 2016; 11: 24-34. https://doi.org/10.1016/j.vhri.2015.12.001
Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine. 2017; 35 (38): 5186-5193.
Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ et al. Rodgers et al. Immune response to 13-valent pneumococal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013; 31 (42): 4765-4774.
Hernández-Porras M. Impacto de la inmunización con vacuna conjugada de neumococo. Revista de Enfermedades Infecciosas en Pediatría. 2009; 22: 67.
Walter EB, Clements DA. Pneumococcal conjugate vaccine: ¿are 3 doses equal to 4 doses? Pediatrics. 2013; 132 (2): e498-499. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23821696
Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013; 132 (2): e324-e332.
Rückinger S, Dagan R, Albers L, Schönberger K, von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine. 2011; 29 (52): 9600-9606.
Von Mollendorf C, Tempia S, Gottberg A, Meiring S, Quan V, Feldman C et al. Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa. PLoS One. 2017; 12: e0179905. https://doi.org/10.1371/journal.pone.0179905
Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL et al. Immunogenicity and safety of single dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017; 123 (21): 4215-4223.
Jallow S, Madhi SA, Madimabe R, Sipambo N, Violari A, Kala U et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying conditions. Vaccine. 2017; 35 (34): 4321-4329.